Thursday 08 June 2023 - 10:11
NOTE: all of our usual telephone and FAX systems are currently down due to a dispute between our landlord and Verizon. We are working to remedy this situation and get our phones back on ASAP.
In the meantime, please use this mobile phone number: 978-715-9327, and this fax number: 781-491-0695.
Thank you for your patience as we work through this unfortunate outage caused by a dispute beyond our control.
Sale: 25% Off !!
For Online Shopping Cart Orders Only
In-Stock Sizes Only - Limited Time Only
See Check-out Page For Further Details
FREE SHIPPING TO THE U.S. AND 32 OTHER COUNTRIES! [Read more].
Search:
R-6300 Rucaparib, Free Base, >99%
Synonyms : [AG-14447]
Related Terms : [Rubraca]

- Size
- US $
- €
- £
- ¥
- 5 mg
- 55
- 51
- 44
- 7,700
- In stock
- 10 mg
- 82
- 76
- 65
- 11,500
- In stock
- 25 mg
- 139
- 129
- 111
- 19,400
- In stock
- 50 mg
- 173
- 161
- 138
- 24,200
- In stock
- 100 mg
- 279
- 260
- 224
- 39,000
- In stock
- 200 mg
- 473
- 441
- 379
- 66,100
- In stock
- 300 mg
- 624
- 582
- 501
- 87,200
- In stock
Note: Our Euro, Pound, and Yen prices are revised regularly to account for currency exchange rate fluctuations.
To receive a Formal Quotation for catalog sizes of this product and/or any other products, please add them to your shopping cart and click on the “REQUEST A QUOTATION” box.
Click Here to Request a Quotation for Larger Quantities
Free Shipping and Handling to the U.S. and 32 Other Countries
- M.W. 323.36
- C19H18FN3O
- [283173-50-2]
- This research compound is the free base form of rucaparib; please see the other form of rucaparib, Cat. No. [R-6399], Rucaparib Phosphate, for further technical information about both of these research compounds. The phosphate salt form of rucaparib is used for some or all rucaparib formulations for use in humans.
- This rucaparib product is the free base, whose CAS number is given above. The CAS number of the phosphate salt form is 459868-92-9.
- Rucaparib (as the camsylate salt) is the active ingredient in the drug product sold under the trade name Rubraca®. This drug is currently approved in a least one country for the maintenance treatment of adult patients with recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer. NOTE: THE RUCAPARIB SOLD BY LC LABORATORIES FOR RESEARCH IS NOT RUBRACA®, AND IS NOT FOR HUMAN USE.
- Sold for laboratory or manufacturing purposes only; not for human, veterinary, food, or household use
- This product is offered for R&D use in accordance with (i) 35 USC 271(e)+A13(1) in the U.S.; (ii) Section 69.1 of Japanese Patent Law in Japan; (iii) Section 11, No. 2 of the German Patent Act of 1981 in Germany; (iv) Section 60, Paragraph 5b of the U.K. Patents Act of 1977 in the U.K.; (v) Sections 55.2(1) and 55.2(6) and other common law exemptions of Canadian patent law; (vi) Section 68B of the Patents Act of 1953 in New Zealand together with the amendment of same by the Statutes Amendment Bill of 2002; (vii) such related legislation and/or case law as may be or become applicable in the aforementioned countries; and (viii) such similar laws and rules as may apply in various other countries.
- Not available in some countries; not available to some institutions; not available for some uses.